PharmTech News

Articles

A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

CSR and Sustainability in the News

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Endo Pharmaceuticals and GVK Biosciences (GVK BIO), a contract research organisation (CRO) based in India, have entered into an agreement to collaborate on the development of small molecules targeting an undisclosed protein. Using its discovery expertise, GVK BIO will deliver a clinical candidate and Endo will be responsible for the development and commercialisation of the product.

Endo Pharmaceuticals and GVK Biosciences Form Research Collaboration

Amy Ritter was Scientific Editor, BioPharm International.

Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.

Ben Venue Laboratories Enters Consent Decree

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.

GSK in Joint Venture for Pediatric Vaccine

AstraZeneca and Ceram Research, a materials development company based in the UK, have signed an agreement whereby Ceram will develop its inorganic-based controlled release technology in a feasibility study for delivering select AstraZeneca compounds.

AstraZeneca and Ceram Sign R&D Agreement

Following its recent acquisition, Actavis (formerly Watson Pharmaceuticals) unveiled its long-term growth strategy during its investor meeting in New York.

Actavis Unveils Long-Term Growth Strategy

Allergan and MAP Pharmaceuticals have entered into a definite merger agreement under which Allergan will purchase all of MAP?s outstanding shares for the price of $25.00 per share.

Allergan to Acquire MAP Pharmaceuticals

FDA has issued a Warning Letter to Hameln Pharmaceuticals GmbH after observing "significant" cGMP violations for finished pharmaceuticals at the company?s facility in Hameln, Germany.

Bio/Pharma News